Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05483140
Other study ID # HA55
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date October 26, 2022
Est. completion date September 2024

Study information

Verified date January 2024
Source Abbott Nutrition
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study (known as clinical audit in UK) will observe and report on a digitally-enabled structured weight management program including use of a meal replacement on clinical and economic outcomes for community-dwelling adults living with type 2 diabetes.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 217
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria: 1. Have a clinical diagnosis of T2DM within the last 6 years 2. Aged 20 - 70 years 3. Have a BMI = 27 kg/m2 4. HbA1c = 48 mmol/mol (= 42mmol/mol if prescribed glucose-lowering agents) 5. Have access to the internet and a computer, smartphone or tablet 6. Ability to read and understand English 7. Willing to provide individual consent Exclusion Criteria: 1. Current insulin use 2. More than two anti-hyperglycemic agents prescribed 3. Recent routine HbA1c = 90 mmol/mol 4. Diagnosed with moderate or severe frailty 5. Diagnosed eating disorder or purging 6. Unable or unwilling to tolerate soy/milk-based meal replacements 7. Myocardial infarction within last 6 months 8. Recent eGFR <30 ml/min/1.73 m2 9. Prescribed SGLT2 inhibitor for diabetic kidney disease (DKD) or left ventricular hypertrophy (LVH) 10. Severe heart failure defined as equivalent to the New York Heart Association grade 3 (NYHA) 11. Current treatment with anti-obesity drugs 12. Learning difficulties that would prevent engagement with the program 13. Having required hospitalization for depression or being prescribed antipsychotic drugs 14. Known cancer 15. Active substance misuse 16. Contraindications to exercise 17. Contraindications to lose weight 18. Mental or physical incapacity that makes self-management inappropriate 19. Pregnant, planning a pregnancy or lactating 20. Currently undergoing palliative care 21. Previous bariatric surgery or on waiting list for bariatric surgery (unless willing to come off waiting list) 22. Unable to commit to long term lifestyle change 23. Known proliferative retinopathy that has not been treated

Study Design


Intervention

Other:
Option 1
Partial meal replacement to achieve 900-1000 kcal/day (4 meal replacement products per day combined with 150-200 kcal from vegetable meals (recipes provided))
Option 2
Partial meal replacement to achieve 900-1000 kcal/day (2 meal replacement products per day combined with one balanced meal (recipes provided))
Option 3
A real food low energy diet to achieve 800-1000 kcal/day (recipes provided)

Locations

Country Name City State
United Kingdom Nhs Tees Valley Ccg Middlesbrough
United Kingdom Nhs Northumberland Ccg Morpeth
United Kingdom Nhs Newcastle Gateshead Ccg Newcastle upon Tyne
United Kingdom Nhs North Tyneside Ccg North Shields

Sponsors (3)

Lead Sponsor Collaborator
Abbott Nutrition Changing Health, National Health Service, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Healthcare Resource Utilization (HRU), including unplanned (non-study-related) (re)hospitalizations, emergency department (ED) visits, and outpatient clinic visits, depending on data Number of unplanned inpatient hospitalizations, outpatient clinic visits, emergency department visits Baseline to 12 Months
Other HRU Cost-Savings service, depending on data availability. Change in cost of overall healthcare resource utilization Baseline to 12 Months
Other Quality of Life (QOL) SF-12 Patient Reported (QOL) questionnaire Baseline to 12 Months
Primary Program Feasibility Participant and HCP completed program questionnaire scored from 0 to 10 where higher score is more favorable Baseline to 12 Months
Primary Program Effectiveness Mean Weight Change Baseline to 12 Months
Secondary Glycemic Control Mean HbA1c change Baseline to 12 Months
Secondary Diabetes Distress Participant completed PAID5 (Problem Areas In Diabetes) diabetes-related emotional distress scale from 0 to 100 where higher rating is less favorable Baseline to 12 Months
Secondary Medication Usage use Medications prescribed from baseline throughout study phases Baseline to 12 Months
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A